Translational studies have revealed that high calpain-2 expression correlates with adverse outcomes in basal-like or triple-negative breast cancer [21], while high calpain-1 expression correlated with poor relapse-free survival in HER2+ breast cancer [22]. Here, CAPN2 is linked to breast cancer.